Yongbo Liu

Yongbo Liu

Auto-generated profile, based on publicly available information

Yongbo Liu

Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine 1 , Shanghai

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
SMShan Miao
Shan Miao
HLHao Li
Hao Li
XSXiaohan Song
Xiaohan Song
YLYongbo Liu
Yongbo Liu
GWGaoyang Wang
Gaoyang Wang
HLHua-Bing Li
Hua-Bing Li
Activation of CD8+ T cells necessitates rapid metabolic reprogramming to fulfill the substantial biosynthetic demands of effector functions. However, the posttranscriptional mechanisms underpinning this process remain obscure. The transfer RNA (tRNA) N1-methyladenine (m1A) modification, essential for tRNA stability and protein translation, has an undefined physiological function in CD8+ T cells, particularly in antitumor responses. Here, we demonstrate that the tRNA m1A “writer” gene Trmt61a enhances the tumor-killing capacity of CD8+ T cells by regulating cholesterol biosynthesis. Deletion of Trmt61a in CD8+ T cells leads to a compromised tumor-killing function in both in vivo and in vitro assays. Mechanistically, tRNA m1A promotes antitumor immunity in CD8+ T cells by enhancing the translation of ATP citrate lyase, a key enzyme for cholesterol biosynthesis. Cholesterol supplementation rescues the impaired tumor-killing function and proliferation of TRMT61A-deficient CD8+ T cells. Our findings highlight tRNA m1A modification as a regulatory checkpoint in cholesterol metabolism in CD8+ T cells, suggesting potential novel strategies for cancer immunotherapy.

13 November 2020 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
YLYongbo Liu
Yongbo Liu
CFcheng fu
cheng fu
GLGang Lu
Gang Lu
JLJie Luo
Jie Luo
SYShaotang Ye
Shaotang Ye
SLShoujun Li
Shoujun Li
The canine influenza virus (CIV) outbreaks have raised concerns as they pose a threat to the health of dogs. The successful construction of a canine influenza (CI) infection model is essential to study the CIV. Here we investigated the pathogenicity of different infectious doses of H3N2 CIV in Beagle dogs. Thirty-seven healthy Beagle dogs were used in the experiment and were infected with 103, 104, 105, and 106 50% egg-infectious doses (EID50). Compared to the dogs in the other three groups, those in the 106 EID50 group presented with obvious clinical symptoms, high virus titer, and typical pathological changes. Considering the ensemble of clinical scores, body temperature, virus shedding, lung lesions, pathological section scores, and visceral virus titers, we determined that 106 EID50 is the minimum infectious dose for the Beagle infection model. The other three infectious doses had almost no clinical symptoms. These results indicate that 106 EID50 is the minimum infectious dose of H3N2 CIV that can cause obvious clinical manifestations and pathological changes associated with CI in Beagle dogs. The theoretical framework developed in this research will guide the establishment of an infection model of CIV for future research.


23 September 2026 in Journal of Hepatology
Verified
Journal Article
Closed access
YLYongbo Liu
Yongbo Liu
BWBingran Wang
Bingran Wang
DSDi Sun
Di Sun
AZAiwei Zhou
Aiwei Zhou
ZCZimeng Cai
Zimeng Cai
QXQiang Xia
Qiang Xia